Reata Pharmaceuticals Inc - Ordinary Shares - Class A

NASDAQ:RETA   3:59:51 PM EDT
30.38
-1.67 (-5.21%)
Products

Reata Pharmaceuticals Announces FDA Filing Acceptance And Priority Review Designation For NDA For Omaveloxolone For Treatment Of Patients With Friedreich's Ataxia

Published: 05/26/2022 11:05 GMT
Reata Pharmaceuticals Inc - Ordinary Shares - Class A (RETA) - Reata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients With Friedreich’s Ataxia.
Reata Pharmaceuticals Inc - Application Assigned a PDUFA Date of November 30, 2022.
Reata Pharmaceuticals Inc - FDA Indicated It is Currently Planning to Hold an Advisory Committee Meeting to Discuss Application.